These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 4630902)
1. [Results of follow-up on advanced cases of pulmonary tuberculosis converted to negative with rifampicin treatment]. Yamamoto M; Isoe K; Nakamura H; Hirose H; Izumi S Kekkaku; 1972 Nov; 47(11):393-7. PubMed ID: 4630902 [No Abstract] [Full Text] [Related]
2. [Bacteriological relapse among the previously treated advanced pulmonary tuberculosis patients whose sputum converted to negative by the rifampicin treatment, with special reference to the duration of rifampicin administration (author's transl)]. Yamamoto M; Morishita M; Hirano Y; Nagata A; Yazaki M Kekkaku; 1974 Jul; 49(7):195-9. PubMed ID: 4214961 [No Abstract] [Full Text] [Related]
3. [Sputum positive conversion among retreatment cases with pulmonary tuberculosis converted to negative by the use of rifampicin (author's transl)]. Ito F; Okochi T; Yamazaki M; Yamamoto Y; Kondo K; Konishiike J; Asahi T Kekkaku; 1979 Jan; 54(1):37-42. PubMed ID: 107360 [No Abstract] [Full Text] [Related]
4. [Effect of rifampicin on the L transformation of a mycobacterial population in patients with destructive pulmonary tuberculosis]. Karachunskiĭ MA; Dorozhkova IR; Chukanov VI; Balta IuE; Kiazimova LM Probl Tuberk; 1986; (9):31-4. PubMed ID: 3097632 [No Abstract] [Full Text] [Related]
5. [A long-term observation on previously treated cases of pulmonary tuberculosis retreated with rifampicin for more than six months (author's transl)]. Tamura M; Takazawa N; Asada T; Ikegaki H; Yamada M; Kushiro S; Tada T Kekkaku; 1979 May; 54(5):285-95. PubMed ID: 113607 [No Abstract] [Full Text] [Related]
6. The Australian rifampicin trial. Proust A; Evans C Med J Aust; 1972 Oct; 2(16):861-7. PubMed ID: 4647286 [No Abstract] [Full Text] [Related]
7. Rifampicin in the retreatment and original treatment of advanced pulmonary tuberculosis. Gyselen A Bull Int Union Tuberc; 1970 Jun; 43():60-3. PubMed ID: 4987555 [No Abstract] [Full Text] [Related]
8. [Rifampicin treatment for pulmonary tuberculosis--effectiveness of rifampicin on tubercle bacilli in pulmonary lesions (author's transl)]. Kameda K; Okamura S; Yamamoto S; Iwai K Kekkaku; 1975 Jul; 50(7):185-9. PubMed ID: 810614 [No Abstract] [Full Text] [Related]
9. [Bacteriologic test during rifampicin treatment]. Ivaldy F Rev Tuberc Pneumol (Paris); 1969; 33(6):818-20. PubMed ID: 4989191 [No Abstract] [Full Text] [Related]
10. [Neutralization of the sputum in newly detected patients with pulmonary tuberculosis treated during the years 1967 to 1970]. Panajotović H; Marsenić B Plucne Bolesti Tuberk; 1974; 26 Suppl 2():105-9. PubMed ID: 4216916 [No Abstract] [Full Text] [Related]
11. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM; Goldberg SV Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [TBL] [Abstract][Full Text] [Related]
12. [The relation between bacilli negative conversion rate and the number of combined sensitive antituberculous drugs in intermittent administration of rifampicin for severe pulmonary tuberculosis]. Tamura M; Yamazaki A; Tamura T; Takano S; Yamazaki M Kekkaku; 1973 Jul; 48(7):297-302. PubMed ID: 4200058 [No Abstract] [Full Text] [Related]
13. [Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy]. Xu WG; Gao Z; Fan BD Zhonghua Jie He He Hu Xi Za Zhi; 2003 Feb; 26(2):74-6. PubMed ID: 12783655 [TBL] [Abstract][Full Text] [Related]
14. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516 [TBL] [Abstract][Full Text] [Related]
15. [Anatomic and bacteriologic testing of rifampicin effectiveness in treatment of pulmonary tuberculosis]. Morère P; Stain JP; Hubert J; Chauvet MC Rev Tuberc Pneumol (Paris); 1970; 34(3):434-8. PubMed ID: 4994941 [No Abstract] [Full Text] [Related]
16. [Dynamics of the release of bacilli and the closing of caverns in newly identified tuberculosis patients undergoing different chemotherapeutic regimens]. Muratov VV; Pashkov IuN; Pospelov VV Probl Tuberk; 1981 Dec; (12):30-4. PubMed ID: 6801646 [No Abstract] [Full Text] [Related]
17. [Incidence and clinical significance of visible but not viable bacilli in patients with pulmonary tuberculosis]. Krychniak W; Araszkiewicz W; Zych D; Janowiec M; Pelczarska B Gruzlica; 1975 Sep; 43(9):785-92. PubMed ID: 808444 [No Abstract] [Full Text] [Related]
18. [Retreatment of pulmonary tuberculosis--duration of chemotherapy]. Wada M; Seita A; Mori T; Ogata H; Sugie T; Sugita H Kekkaku; 1993 Jul; 68(7):469-78. PubMed ID: 8361115 [TBL] [Abstract][Full Text] [Related]
19. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey. Sanders M; Van Deun A; Ntakirutimana D; Masabo JP; Rukundo J; Rigouts L; Fissette K; Portaelst F Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257 [TBL] [Abstract][Full Text] [Related]
20. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]